Evidence map›Paper›PMID 40741039›Full record

ArticleFrontiers in cell death2024

Die Hard: Necroptosis and its Impact on Age-Dependent Neuroinflammatory Diseases.

Kaitlan Smith, Meagan Colie, Trinity Moore, Jonathan C Schisler

Abstract read
In one paragraph

Article in Frontiers in cell death, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Necroptosis in Down Syndrome.Cell death & disease · 2026
    Article
  2. Review
  3. Non-canonical cell death in neurodegeneration: emerging mechanisms and therapeutic Frontiers.Apoptosis : an international journal on programmed cell death · 2026
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kaitlan SmithDepartment of Pharmacology, McAllister Heart Institute, The University of North Carolina at Chapel Hill, NC, USA.
Meagan ColieDepartment of Pharmacology, McAllister Heart Institute, The University of North Carolina at Chapel Hill, NC, USA.
Trinity MooreDepartment of Pharmacology, McAllister Heart Institute, The University of North Carolina at Chapel Hill, NC, USA.
Jonathan C SchislerDepartment of Pharmacology, McAllister Heart Institute, The University of North Carolina at Chapel Hill, NC, USA.

Funding

Dual CHIP Functions Control Tau Triage In Alzheimer's DiseaseR01AG061188 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COHEN, TODD JONATHAN, SCHISLER, JONATHAN C. · 2019 to 2023
$3.1M
Protein quality control in age-related diseasesR01AG066710 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SCHISLER, JONATHAN C. · 2020 to 2024
$2.4M
NIA NIH HHS R01 AG061188NIA NIH HHS R01 AG066710
6 · The paper itself

Abstract

The pro-inflammatory form of cellular death, necroptosis, is critical to age-related pathologies. Necroptosis primarily functions as an antipathogenic and antitumor biological mechanism by triggering inflammatory pathways within rogue cell bodies, resulting in cell death. Several neurodegenerative conditions have hallmarks of necroptosis, suggesting a potential role for this cell death pathway in the pathogenesis of neuroinflammation and neuronal cell death, likely through the release of pro-inflammatory cytokines that perpetuate inflammatory signaling and neurodegeneration. The receptor-interacting protein kinases 1 and 3 (RIPK1/3) signaling cascade is critical to necroptosis regulation; however, the complete mechanism behind necroptotic activation, regulation, and resolution remains incomplete. In cases where necroptosis is disadvantageous, such as neurodegenerative diseases, we lack effective pharmacological suppressors of necroptosis that could mitigate disease progression. Targeting regulatory proteins within the necroptotic signaling pathway has shown promise; however, the need for specific inhibitors limits therapeutic opportunities. This review focuses on necroptosis and its role in neuroinflammation and neurodegeneration in age-dependent disorders. We comprehensively detail the known necroptotic signaling pathways and potential signaling partners and discuss the ongoing therapeutic efforts in targeting and preventing active necroptotic signaling and their relevance to neuroprotection.

Indexed as

cellular deathinflammationnecroptosisneurodegenerationneuroinflammation

Identifiers

PMID40741039
PMCPMC12309338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.